Thomas Woiwode, Director at CRISPR Therapeutics AG (CRSP), sold 59,470 shares at $50.29 ($3.0M) on 2018-04-30, disclosed to the SEC on 2018-05-02.
Open-market sale of $3.0M CRSP by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.26 | 874 | $44K | 1.5% |
| 2 | $50.29 | 788 | $40K | 1.3% |
| 3 | $50.29 | 2,044 | $103K | 3.4% |
| 4 | $50.29 | 2,044 | $103K | 3.4% |
| 5 | $50.29 | 26,860 | $1.4M | 45.2% |
| 6 | $50.29 | 26,860 |
| $1.4M |
| 45.2% |
| Total | $50.29 avg | 59,470 | $3.0M | 100% |
| Filing → |
| ALGS | BUY | 2020-10-20 | $3.0M | — | Filing → |
| PASG | BUY | 2020-03-03 | $4.0M | — | Filing → |
| CRSP | SELL | 2018-05-17 | $2.6M | — | Filing → |